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Summary Cyclic AMP binding proteins were measured in the primary tumour from 100 patients with
non-disseminated breast cancer selected on the basis that sufficient tumour material was available for analysis.
These measurements have been related to factors of established prognostic value and to the patients'
disease-free interval and survival. There was a wide variation in amounts of binding proteins in different
tumours. Values were significantly higher (P<0.05) in oestrogen receptor-negative tumours but no statistically
significant correlations were apparent between levels and tumour grade or whether the patients had lymph
node metastasis or adjuvant treatment. However, levels were significantly higher in patients whose disease
recurred within 3 years of primary treatment as compared with those who remained disease-free. Using a
retrospectively determined cut off point of 8 pmol mg-' cytosol protein, it was shown that patients with
tumour cyclic AMP binding in excess of this value had a significantly greater chance of developing recurrent
disease and poorer survival rates (P<0.001 by Cox analysis) than those with lower levels. This remained true
when other prognostic factors were taken into account in a multivariate analysis. It is suggested that the level
of tumour cyclic AMP binding may be an independent prognostic factor for patients with early breast cancer.
Studies of rodent mammary carcinomas have suggested that
levels of cyclic AMP binding proteins may differ in tumours
according to their degree of autonomy and their growth
status (Bodwin & Cho-Chung, 1978; Cho-Chung et al.,
1981). However, the corresponding information is not
available in human tumours although we and others have
shown that levels of cyclic AMP binding may help to define
groups of breast cancers with differing likelihood of response
to endocrine therapy (Kvinnsland et al., 1983; Watson et al.,
1987). The aim of the present investigation was to determine
whether cyclic AMP binding proteins are of prognostic value
in patients with early breast cancer by relating tumour levels
to disease-free interval and other factors influencing outcome
of disease.
Methods and materials
Patients
One hundred women with histologically proven invasive
breast cancer and no evidence of distant metastatic disease
on routine staging were included in the study between 1979
and 1984, follow-up being last assessed in 1988. Patients were
selected on the basis that sufficient tumour was available for
assay of cyclic AMP binding proteins after material had been
taken for histopathological diagnosis and oestrogen receptor
measurement (840 women with operable breast cancer were
treated in the unit by some form of surgical excision of the
primary tumour between 1979 and 1984). Primary surgical
treatment was either simple mastectomy (with either axillary
sampling and radiotherapy or axillary clearance) or wide
local excision with axillary sampling; adjuvant systemic
therapy was given to 54 patients (40 receiving endocrine
agents and 14 chemotherapy). Lymph node status was
assessed in 98 patients by histological examination of axillary
nodes. The menopausal status was classified in all women as
premenopausal (regular menstrual periods), post-menopausal
(at least 3 years beyond their last menstrual period) or
perimenopausal (less than 3 years since their last menstrual
period).
Tumour
In all cases, material was obtained from the primary tumour
either by biopsy or at mastectomy. This was transported on
ice to a cold room and immediately processed (34 tumours)
or stored in liquid N2 until assayed (66 tumours stored
between 1 week and 5 years).
Measurement ofcyclic AMP binding
The method used was that described previously (Miller et al.,
1983). Briefly, a cytosol was prepared at O°C by homogenis-
ing tumour in 20 mM Tris buffer (w/v 1:10) and centrifuging
at 105,000g for 1 h at 4C. The resulting cytosol (50pl) was
incubated with 5'8' 'H-cyclic AMP (1001,l, 25 nM) with or
without varying concentrations of radio-inert cyclic AMP.
Each system was set up in duplicate and incubated at room
temperature for 3 h. Protein bound cyclic AMP was
separated from free nucleotide by filtration through Millipore
filters (HAWP0.451im). Filters were dried and counted in
Micellar fluor NE260, Nuclear Enterprises (5 ml). The dis-
sociation constant of binding and concentration of binding
sites were determined by Scratchard analysis (1949). Results
were expressed as pmol binding protein per mg soluble
cytosol protein, protein content being determined by the
method of Bradford (1976).
Steroid receptors
Levels of steroid receptors were determined by saturation
analysis, those for oestrogen (ER) by the method of Hawkins
et al. (1975) and those for progestogen (PgR) by that of
Miller et al. (1983). Tumours containing >5 fmol ER mg-'
protein were designated ER-positive and those containing
>15 fmol PgR mg-' protein were designated PgR-positive.
Tumourgrade
Paraffin-embedded specimens were cut and histological sec-
tions were stained with haematoxylin and eosin. These were
scored for tumour grade as described by Bloom and Richard-
son (1959), analysis being performed retrospectively by
J.M.D., who was not aware of the results of other estima-
tions.
Statistical methods
The relationship of cyclic AMP binding protein levels to
other prognostic factors and to disease status at 36 months
was tested by Wilcoxon rank sum tests or Kendall rank
correlation. Cox proportional hazards analysis was used to
test whether time to recurrence or death was significantly
associated with individual factors or combinations of them.
Correspondence: W.R. Miller.
Received 8 May 1989; and in revised form 5 September 1989.
Br. J. Cancer (1990), 61, 263-266 '." Macmillan Press Ltd., 1990264 W.R. MILLER et al.
Results
Cyclic AMP binding protein activity was detected in cytosols
from all 100 primary breast cancers with levels varying from
0.85 to 15.05 pmol mg-' cytosol protein (median value
4.08 pmol mg-' cytosol protein) as shown in Figure 1.
In order to determine factors which might be responsible
for the wide range of values, levels of cyclic AMP binding
proteins were related to patients' menopausal status, lymph
node involvement, clinical stage, tumour grade and steroid
receptors.
With regard to menopausal status, 21 patients were
premenopausal, eight were perimenopausal and 71 were post-
menopausal. No significant differences were detected between
any of the sub-groups (data not shown).
Oestrogen receptors were detected in in 77 tumours and
absent in the remaining 23. The median level of cyclic AMP
binding proteins was significantly higher (P<0.05) in the
ER -ve tumours compared with those with receptors
(Figure 2a). Assays for progestogen receptors were performed
in 78 tumours of which 33 were positive. No significant
difference was found in levels of cyclic AMP binding protein
between PgR + ve and PgR -ve tumours (Figure 2b).
Levels of tumour cyclic AMP binding proteins subdivided
according to tumour grade, the patient's histological lymph
node status and clinical T stage are shown in Figure 3. No
significant differences between the sub-groups were detected.
The group of grade 1 tumours had a lower median valuc
than those of other grades but this was not statistically
significant, perhaps because of the relatively small number of
grade I tumours.
A minimum follow-up of 36 months was available on all
patients. Levels of cyclic AMP binding proteins in tumours
from patients who were either disease-free or had recurrent
disease within 36 months are compared in Figure 4.
Although there was an overlap in values of cyclic AMP
binding between the groups, the median value for tumours
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Figure 2 Levels of cyclic AMP binding proteins in (a) oestrogen
receptor positive ( + ve) and negative tumours (-ve). Difference
between the groups was significant by Wilcoxon Rank Test,
P<0.05. (b) Progestogen receptor positive ( + ve) and negative
(-ve) tumours. No significant differences between the groups.
Horizontal lines represent median values.
associated with early recurrence (26 patients) was over 2-fold
higher than that in tumours from the patients remaining
disease-free (74). The difference in tumour cyclic AMP bin-
ding between these groups of patients was highly significant
(P< 0.001).
In order to determine the value of tumour cyclic AMP
binding which gave the maximum discrimination between
tumours associated with early and non-recurrence, the data
were retrospectively analysed by checking misclassification
rates for a range of possible cut-off values. It was found that
a value of 8 pmol mg-' cytosol protein minimised the percen-
tage of patients misclassified at 16%. This value was subse-
quently used in a Cox analysis of disease-free interval (DFI)
and survival data using the total follow-up data available on
the patients (rather than performing analysis at 36 months).
Data on DFI are shown in Figure 5 and indicate that
patients with tumours having cyclic AMP binding proteins
greater than 8 pmol mg-' cytosol protein had a significantly
increased chance of developing recurrence relative to patients
with a lower tumour cyclic AMP binding. This difference
remained large even at 5 years.
Survival curves using death from cancer as an end-point
are shown in Figure 6 and indicate that tumours with high
cyclic AMP binding are significantly associated with poorer
survival.
Multivariate analysis of the same data was performed,
including menstrual status, clinical stage, lymph node
involvement, tumour grade, receptor status and adjuvant
therapy in the model. The results are shown in Table I and
indicate that in this group of patients only level of cyclic
AMP binding protein was of significance in predicting both
early recurrence and survival, although oestrogen receptor
status predicted for early recurrence even when the data were
adjusted for the effect of cyclic AMP binding.
Discussion
I
Figure I Levels of cyclic AMP binding proteins in cytosols of
100 primary breast cancers. Horizontal line represents median
value.
Although we and others have indicated that the level of
tumour cyclic AMP binding proteins may, in combination
with ER, be helpful in predicting response to endocrine
therapy in patients with advanced breast cancer (Kvinnsland
et al., 1983; Watson et al., 1987), we believe that the present
paper is the first report that cyclic AMP binding proteins
may be of prognostic value in patients with symptomatic
breast cancer. Thus patients presenting with recurrent disease
within 36 months of primary treatment had tumours with
significantly higher levels ofcyclic AMP binding protein thanCYCLIC AMP BINDING PROTEINS 265
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Figure 3 Levels of tumour cyclic AMP binding proteins from patients subdivided according to (a) whether axillary lymph nodes
were pathologically involved with tumour ( + ve) or not (-ve); (b) tumour histological grade; (c) clinical T stage. Horizontal lines
represent median values. No significant differences between the groups by Wilcoxon rank test.
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Figure 4 Levels of tumour cyclic AMP binding proteins in
patients remaining disease-free (NR) or having recurrent disease
(R) within 36 months of primary treatment. Difference between
the groups was significant by Wilcoxon rank test, P<0.001.
Horizontal lines represent median values.
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Figure 5 Disease-free survival curves for patients with tumour
cyclic AMP binding values <8 pmol mg-' protein and
>8 pmol mg-' protein. Significant difference between the curves
by Cox analysis, P<0.001.
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Figure 6 Actual survival curves for patients with tumour cyclic
AMP binding values <8 pmol mg-' protein and >8 pmol mg-'
protein. Significant difference between the curves by Cox analysis,
P<0.001.
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Table I Significance values for recurrence and death for factors under
study Pvalues are shown for the significance from the Cox analysis for
each factor when entered alone and also when adjusted for the effect of
cAMP binding.
Recurrence Death
Adjustedfor Adjustedfor
Factor Alone cAMP binding Alone cAMP binding
cAMP binding <0.001 - <0.001 -
Menstrual status 0.71 0.26 0.44 0.57
ER status 0.03 0.02 0.15 0.19
PgR status 0.24 0.19 0.16 0.24
Lymph node status 0.09 0.28 0.21 0.20
Stage 0.06 0.60 0.13 0.85
Grade 0.30 0.21 0.15 0.10
Adjuant therapy 0.94 0.42 0.97 0.42
individuals remaining disease-free. Retrospective analysis of
the data showed that a value of 8 pmol mg-' cytosol protein
gave optimal discrimination between patients who developed
recurrent disease and those remaining disease-free. Although
36 months represents a relatively short follow-up in the
natural history of breast cancer, it should be noted that
survival curves for the total follow-up data base showed clear
differences in rates of recurrence between patients with high
and low tumour cyclic AMP binding, even after 5 years of
follow-up. This would suggest that level of tumour cyclic
AMP binding protein is not merely a marker of rapid recur-
rence but may discriminate at longer time intervals.
Apart from the relationship with oestrogen receptors, no
statistically significant correlation was detected between level
of cyclic AMP binding proteins and other factors previously
suggested to be of prognostic value, i.e. lymph node meta-
stasis, tumour stage, grade and steroid receptor status. It
would therefore seem that cyclic AMP binding proteins are
independent of these parameters. That this is so is confirmed
by multivariate analysis of the data, which shows that only
cyclic AMP binding proteins and oestrogen receptor status
were of significance in determining disease-free interval and
only cyclic AMP binding proteins were statistically associated
with overall survival. Other factors, such as lymph node
involvement and T stage, showed a tendency to be associated
with early recurrence but this did not reach statistical
significance. Why these parameters, which in many studies
are significantly associated with prognosis, were not more
influential in the present group of patients is unclear. The
data base does not represent a consecutive series of patients
and constitues only 12% of those treated for operable breast
cancer within one surgical unit. However, it is emphasised
that no selection bias was applied apart from there being
sufficient tumour for assay after material had been taken for
histological diagnosis and measurement of oestrogen recep-
tors. In general this meant that few clinical To and T,
tumours were available for study.
Furthermore, although cyclic AMP binding proteins help
to identify endocrine responsive tumours it seem unlikely that
this is a factor contributing to the present findings. Cyclic
AMP binding proteins were predictive of early recurrence
irrespective of whether adjuvant endocrine treatment was
administered.
It remains to be determined whether levels of cyclic AMP
binding protein are simply markers of poor prognosis or are
causally involved in aggressive tumour behaviour. There have
been suggestions that during tumour growth, levels of cyclic
AMP binding proteins are normally low but increase when
cellular regression occurs (Bodwin & Cho-Chung, 1978). A
further hypothesis is that if, during active growth, cytoplas-
mic cyclic AMP binding protein levels are paradoxically high,
control mechanisms have become defective and growth will
be unregulated and unlikely to respond to normal restraints
(Cho-Chung, 1980). If this is the case, levels of cyclic AMP
binding protein might not only reflect proliferation rates but
also degree of autonomy.
Measurements of cyclic AMP binding proteins may
therefore be useful in the management of patients with early
breast cancer in terms of identifying those who have aggres-
sive disease and would benefit from early intervention with
adjuvant therapy. Assays of tumour cyclic AMP binding
proteins are relatively easy to perform and do not require
sophisticated methodology. Determinations are quantitative
and our unpublished data indicate that valid results may be
obtained from tumours stored in liquid N2 for up to 5 years.
Only small amounts of material (100-200 mg) are required
for assay, although tumour heterogeneity may dictate that
representative samples are taken, particularly in large cancers
(Senbanjo et al., 1986).
Finally it is emphasised that the present study has been
based on retrospective analysis of a relatively small number
of patients with comparatively short follow-up. It is felt,
however, that the discriminating prognostic power of tumour
cyclic AMP binding proteins shows sufficient promise to
merit a prospective investigation.
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